IBD treatment is undergoing a transformation with an expanding repertoire of drugs targeting
different aspects of the immune response. Three novel classes of drugs have emerged in the …

Inflammatory bowel diseases (IBDs) are thought to develop as a result of complex
interactions between host genetics, the immune system and the environment including the …

The management of inflammatory bowel disease (IBD) has been transformed over the last
two decades by the arrival of tumor necrosis factor (TNF) antagonist agents. Recently …

The advent of anti-TNF agents as the first approved targeted therapy in the treatment of
inflammatory bowel disease (IBD) patients has made a major impact on our existing …

Purpose of review This article reviews current treatment options and strategies and provides
an update on the status of drug development programs of new therapeutic agents for …

The completion of the human genome project in 2003 represented a major scientific
landmark, ushering in a new era with hopes and expectations of fresh insights into disease …

The etiology of inflammatory bowel disease (IBD) is not fully understood but is likely
influenced by numerous factors such as genetic predisposition, environmental factors, like …

Crohn's disease and ulcerative colitis are increasingly prevalent, relapsing and remitting
inflammatory bowel diseases (IBDs) with variable disease courses and complications. Their …

Introduction: Cytokines represent the key pathophysiologic elements that govern the
initiation, progression, and, in some circumstances, the resolution of the inflammation …

Infiltration of the lamina propria by inflammatory CD4+ T-cell populations is a key
characteristic of chronic intestinal inflammation. Memory-phenotype CD4+ T-cell frequencies …